Jubilant Life up over 4% on USFDA nod for epilepsy injection

Shares of drug firm Jubilant Life Sciences today ended over 4 per cent higher as the company received final approval from the US health regulator for generic Levetiracetam injection, used for treatment of epilepsy, in the American market.
The stock ended the day with a gain of 4.08 per cent at Rs 367.35 on BSE. During the day, it climbed 5.96 per cent to Rs 374.
At NSE, shares of the company rose by 4.29 per cent to close at Rs 368.10.
The company added Rs 230.19 crore to Rs 5,851.19 crore in market valuation.
It has received abbreviated new drug application (ANDA) final approval for Levetiracetam injection USP, 500 mg/5 mL (100 mg/mL) from the United States Food and Drug Administration (USFDA), Jubilant Life Sciences had said in a BSE filing on Friday.

The company's product is the generic version of UCB's Keppra injection in the same strength, it added.
"As on March 31, 2016, Jubilant Life Sciences had a total of 739 filings for formulations, of which 517 have been approved in various regions globally. These include 72 ANDAs filed in the US, of which 44 have been approved and 46 Dossier filings in Europe," the company had said.